ArrowMark Colorado Holdings LLC Acquires 299,289 Shares of The Cooper Companies, Inc. $COO

ArrowMark Colorado Holdings LLC lifted its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 35.1% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,151,464 shares of the medical device company’s stock after buying an additional 299,289 shares during the period. Cooper Companies comprises about 1.5% of ArrowMark Colorado Holdings LLC’s portfolio, making the stock its 14th biggest holding. ArrowMark Colorado Holdings LLC owned about 0.58% of Cooper Companies worth $78,944,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of COO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Cooper Companies by 48.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,407 shares of the medical device company’s stock valued at $1,890,000 after acquiring an additional 7,363 shares during the last quarter. ProShare Advisors LLC lifted its holdings in shares of Cooper Companies by 12.6% in the second quarter. ProShare Advisors LLC now owns 35,635 shares of the medical device company’s stock worth $2,536,000 after acquiring an additional 3,990 shares during the last quarter. Allworth Financial LP boosted its stake in shares of Cooper Companies by 36.6% in the 2nd quarter. Allworth Financial LP now owns 959 shares of the medical device company’s stock valued at $68,000 after purchasing an additional 257 shares in the last quarter. Forsta AP Fonden boosted its stake in shares of Cooper Companies by 1.9% in the 2nd quarter. Forsta AP Fonden now owns 38,400 shares of the medical device company’s stock valued at $2,733,000 after purchasing an additional 700 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Cooper Companies by 2.5% during the 2nd quarter. Geode Capital Management LLC now owns 5,205,615 shares of the medical device company’s stock valued at $368,893,000 after purchasing an additional 127,907 shares during the last quarter. 24.39% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Holly R. Sheffield bought 1,230 shares of the stock in a transaction that occurred on Tuesday, December 16th. The stock was acquired at an average cost of $80.75 per share, with a total value of $99,322.50. Following the transaction, the insider directly owned 39,052 shares in the company, valued at approximately $3,153,449. This trade represents a 3.25% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Albert G. White III bought 10,000 shares of the business’s stock in a transaction on Tuesday, December 16th. The shares were bought at an average cost of $80.80 per share, for a total transaction of $808,000.00. Following the completion of the acquisition, the chief executive officer directly owned 236,151 shares in the company, valued at approximately $19,081,000.80. This trade represents a 4.42% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 16,014 shares of company stock valued at $1,304,416 over the last quarter. 2.08% of the stock is currently owned by company insiders.

Cooper Companies Stock Down 2.2%

NASDAQ:COO opened at $69.92 on Friday. The firm’s 50 day simple moving average is $81.23 and its 200 day simple moving average is $75.96. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.34 and a quick ratio of 0.79. The Cooper Companies, Inc. has a one year low of $61.78 and a one year high of $89.83. The company has a market cap of $13.64 billion, a PE ratio of 34.61, a P/E/G ratio of 1.80 and a beta of 1.02.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Thursday, March 5th. The medical device company reported $1.10 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.07. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.02 billion. Cooper Companies had a net margin of 9.67% and a return on equity of 10.34%. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.92 EPS. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS. On average, research analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

Analyst Ratings Changes

COO has been the subject of a number of research analyst reports. JPMorgan Chase & Co. upped their price objective on shares of Cooper Companies from $66.00 to $78.00 and gave the stock a “neutral” rating in a research report on Friday, December 5th. Barclays boosted their target price on shares of Cooper Companies from $98.00 to $103.00 and gave the stock an “overweight” rating in a research note on Friday, March 6th. Morgan Stanley upped their price target on shares of Cooper Companies from $76.00 to $83.00 and gave the stock an “equal weight” rating in a report on Monday, December 8th. Wells Fargo & Company increased their price target on Cooper Companies from $72.00 to $82.00 and gave the company an “equal weight” rating in a research note on Friday, December 5th. Finally, KeyCorp reissued a “sector weight” rating on shares of Cooper Companies in a report on Friday, December 5th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $90.79.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.